Basiliximab vs Nivolumab

## Basiliximab vs Nivolumab: Overview

This comparison examines the pharmacological differences between **Basiliximab** and **Nivolumab**.

## Mechanism of Action

**Nivolumab**: Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.

## Pharmacokinetics

**Half-life**: Basiliximab — N/A; Nivolumab — 27 days.

## Chemical Properties

**Type**: Basiliximab — Antibody; Nivolumab — Antibody.